Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Oct;74(7):1120–1125. doi: 10.1038/bjc.1996.500

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

I Soubeyran 1, N Quénel 1, J M Coindre 1, F Bonichon 1, M Durand 1, J Wafflart 1, L Mauriac 1
PMCID: PMC2077113  PMID: 8855985

Abstract

Tamoxifen as sole initial therapy is gaining importance in the management of post-menopausal breast cancer patients. Age oestrogen (ER) and progesterone (PR) receptor status are accurately considered to select patients for hormonal treatment. However, additional markers are needed. By immunohistochemistry (IHC), we studied tumour expression of ER, PR, pS2, c-erbB-2 and glutathione S-transferase pi (GST pi) on initial core biopsies of 208 post-menopausal patients with a non-metastatic invasive ductal carcinoma, treated by neoadjuvant tamoxifen therapy. A good response to tamoxifen was defined as tumoral regression > or = 50% (110 patients). Relationship between response and age, tumour size, T, N, histological grade, ER and PR contents evaluated by radioimmunoassay, ER, PR, pS2, c-erbB-2 and GST pi expression evaluated by IHC were studied. Univariate and multivariate analysis showed that tumoral regression was linked only to pS2 (P = 0.004) and ER (P = 0.018) IHC expression. According to the immunohistochemical profile, three groups could be defined: pS2- and ER-positive tumours, pS2- or ER-positive tumours and pS2- and ER-negative tumours with response rates of 60%, 45% and 8% respectively. Although prospective studies are needed to confirm these results, we conclude that pS2 and ER immunohistochemical status are useful tools for predicting tumour regression with neoadjuvant tamoxifen in post-menopausal breast carcinoma patients.

Full text

PDF
1120

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akhtar S. S., Allan S. G., Rodger A., Chetty U. D., Smyth J. F., Leonard R. C. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol. 1991 Feb;17(1):30–35. [PubMed] [Google Scholar]
  2. Bergman L., van Dongen J. A., van Ooijen B., van Leeuwen F. E. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat. 1995 Apr;34(1):77–83. doi: 10.1007/BF00666494. [DOI] [PubMed] [Google Scholar]
  3. Bradbeer J. W., Kyngdon J. Primary treatment of breast cancer in elderly women with Tamoxifen. Clin Oncol. 1983 Mar;9(1):31–34. [PubMed] [Google Scholar]
  4. Coombes R. C., Powles T. J., Berger U., Wilson P., McClelland R. A., Gazet J. C., Trott P. A., Ford H. T. Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet. 1987 Sep 26;2(8561):701–703. doi: 10.1016/s0140-6736(87)91071-3. [DOI] [PubMed] [Google Scholar]
  5. Davies N., Moir G., Carpenter R., Cuthbert A., Herbert A., Royle G. T., Taylor I. ERICA predicts response to tamoxifen in elderly women with breast cancer. Ann R Coll Surg Engl. 1991 Nov;73(6):361–363. [PMC free article] [PubMed] [Google Scholar]
  6. Dorion-Bonnet F., Quénel N., Coindre J. M., Mauriac L., Bonichon F., Durand M., Wafflart J., Moscow J. A., Cowan K. H., Gualde N. Expression of the GST pi gene and response to tamoxifen therapy in locally advanced breast carcinomas. Ann N Y Acad Sci. 1993 Nov 30;698:182–185. doi: 10.1111/j.1749-6632.1993.tb17207.x. [DOI] [PubMed] [Google Scholar]
  7. Foudraine N. A., Verhoef L. C., Burghouts J. T. Tamoxifen as sole therapy for primary breast cancer in the elderly patient. Eur J Cancer. 1992;28A(4-5):900–903. doi: 10.1016/0959-8049(92)90146-s. [DOI] [PubMed] [Google Scholar]
  8. Frigo B., Pilotti S., Zurrida S., Ermellino L., Manzari A., Rilke F. Analysis of estrogen and progesterone receptors on preoperative fine-needle aspirates. Breast Cancer Res Treat. 1995;33(2):179–184. doi: 10.1007/BF00682725. [DOI] [PubMed] [Google Scholar]
  9. Gaskell D. J., Hawkins R. A., Sangsterl K., Chetty U., Forrest A. P. Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet. 1989 May 13;1(8646):1044–1046. doi: 10.1016/s0140-6736(89)92445-8. [DOI] [PubMed] [Google Scholar]
  10. Gaskell D. J., Hawkins R. A., de Carteret S., Chetty U., Sangster K., Forrest A. P. Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg. 1992 Dec;79(12):1317–1320. doi: 10.1002/bjs.1800791225. [DOI] [PubMed] [Google Scholar]
  11. Gazet J. C., Markopoulos C., Ford H. T., Coombes R. C., Bland J. M., Dixon R. C. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988 Mar 26;1(8587):679–681. doi: 10.1016/s0140-6736(88)91478-x. [DOI] [PubMed] [Google Scholar]
  12. Gilbert L., Elwood L. J., Merino M., Masood S., Barnes R., Steinberg S. M., Lazarous D. F., Pierce L., d'Angelo T., Moscow J. A. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol. 1993 Jan;11(1):49–58. doi: 10.1200/JCO.1993.11.1.49. [DOI] [PubMed] [Google Scholar]
  13. Henry J. A., Nicholson S., Hennessy C., Lennard T. W., May F. E., Westley B. R. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer. 1990 Jan;61(1):32–38. doi: 10.1038/bjc.1990.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Henry J. A., Piggott N. H., Mallick U. K., Nicholson S., Farndon J. R., Westley B. R., May F. E. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer. 1991 Apr;63(4):615–622. doi: 10.1038/bjc.1991.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hill C. Valeur pronostique d'une variable continue et point de césure optimal. Bull Cancer. 1993 Aug;80(8):649–652. [PubMed] [Google Scholar]
  16. Horobin J. M., Preece P. E., Dewar J. A., Wood R. A., Cuschieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991 Feb;78(2):213–217. doi: 10.1002/bjs.1800780228. [DOI] [PubMed] [Google Scholar]
  17. Hurlimann J., Gebhard S., Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology. 1993 Sep;23(3):239–248. doi: 10.1111/j.1365-2559.1993.tb01196.x. [DOI] [PubMed] [Google Scholar]
  18. Katz R. L., Patel S., Sneige N., Fritsche H. A., Jr, Hortobagyi G. N., Ames F. C., Brooks T., Ordonez N. G. Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat. 1990 May;15(3):191–203. doi: 10.1007/BF01806356. [DOI] [PubMed] [Google Scholar]
  19. Klijn J. G., Berns E. M., Foekens J. A. Prognostic factors and response to therapy in breast cancer. Cancer Surv. 1993;18:165–198. [PubMed] [Google Scholar]
  20. Luqmani Y. A., Ricketts D., Ryall G., Turnbull L., Law M., Coombes R. C. Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int J Cancer. 1993 Jun 19;54(4):619–623. doi: 10.1002/ijc.2910540416. [DOI] [PubMed] [Google Scholar]
  21. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 1982 Dec 20;10(24):7895–7903. doi: 10.1093/nar/10.24.7895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mauriac L., Durand M., Chauvergne J., David M., Wafflart J. Les cancers du sein à haut risque métastatique: prédiction de la survie par les récepteurs stéroïdiens. Bull Cancer. 1989;76(1):33–41. [PubMed] [Google Scholar]
  23. Mauriac L., Wafflart J., Durand M., Parsi B., de Mascarel I., Trojani M., Meugé-Moraw C. Apport de la drill-biopsie dans le bilan préthérapeutique des adénocarcinomes mammaires. Bull Cancer. 1981;68(5):417–421. [PubMed] [Google Scholar]
  24. McCarty K. S., Jr, Miller L. S., Cox E. B., Konrath J., McCarty K. S., Sr Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985 Aug;109(8):716–721. [PubMed] [Google Scholar]
  25. McClelland R. A., Berger U., Miller L. S., Powles T. J., Coombes R. C. Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol. 1986 Aug;4(8):1171–1176. doi: 10.1200/JCO.1986.4.8.1171. [DOI] [PubMed] [Google Scholar]
  26. Nicholson R. I., McClelland R. A., Finlay P., Eaton C. L., Gullick W. J., Dixon A. R., Robertson J. F., Ellis I. O., Blamey R. W. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 1993;29A(7):1018–1023. doi: 10.1016/s0959-8049(05)80215-1. [DOI] [PubMed] [Google Scholar]
  27. Pertschuk L. P., Eisenberg K. B., Carter A. C., Feldman J. G. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer. 1985 Apr 1;55(7):1513–1518. doi: 10.1002/1097-0142(19850401)55:7<1513::aid-cncr2820550717>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  28. Pertschuk L. P., Kim D. S., Nayer K., Feldman J. G., Eisenberg K. B., Carter A. C., Rong Z. T., Thelmo W. L., Fleisher J., Greene G. L. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer. 1990 Oct 15;66(8):1663–1670. doi: 10.1002/1097-0142(19901015)66:8<1663::aid-cncr2820660802>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  29. Quénel N., Wafflart J., Bonichon F., de Mascarel I., Trojani M., Durand M., Avril A., Coindre J. M. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 1995 Sep;35(3):283–291. doi: 10.1007/BF00665980. [DOI] [PubMed] [Google Scholar]
  30. Ravdin P. M., Green S., Dorr T. M., McGuire W. L., Fabian C., Pugh R. P., Carter R. D., Rivkin S. E., Borst J. R., Belt R. J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1284–1291. doi: 10.1200/JCO.1992.10.8.1284. [DOI] [PubMed] [Google Scholar]
  31. Rilke F., Colnaghi M. I., Cascinelli N., Andreola S., Baldini M. T., Bufalino R., Della Porta G., Ménard S., Pierotti M. A., Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991 Aug 19;49(1):44–49. doi: 10.1002/ijc.2910490109. [DOI] [PubMed] [Google Scholar]
  32. Robertson J. F., Bates K., Pearson D., Blamey R. W., Nicholson R. I. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer. 1992 May;65(5):727–730. doi: 10.1038/bjc.1992.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Robertson J. F., Ellis I. O., Elston C. W., Blamey R. W. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer. 1992;28A(4-5):908–910. doi: 10.1016/0959-8049(92)90148-u. [DOI] [PubMed] [Google Scholar]
  34. Schwartz L. H., Koerner F. C., Edgerton S. M., Sawicka J. M., Rio M. C., Bellocq J. P., Chambon P., Thor A. D. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 1991 Jan 15;51(2):624–628. [PubMed] [Google Scholar]
  35. Simon R., Altman D. G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994 Jun;69(6):979–985. doi: 10.1038/bjc.1994.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Soubeyran I., Quénel N., Mauriac L., Durand M., Bonichon F., Coindre J-M Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. Br J Cancer. 1996 Mar;73(6):735–743. doi: 10.1038/bjc.1996.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Soubeyran I., Wafflart J., Bonichon F., de Mascarel I., Trojani M., Durand M., Avril A., Coindre J. M. Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 1995 May;34(2):119–128. doi: 10.1007/BF00665784. [DOI] [PubMed] [Google Scholar]
  38. Williams M. R., Gilson D., Marsh L., Morgan D. A., Nicholson R. I., Elston C. W., Griffiths K., Blamey R. W. The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol. 1988 Jun;14(3):235–240. [PubMed] [Google Scholar]
  39. Wilson Y. G., Rhodes M., Ibrahim N. B., Padfield C. J., Cawthorn S. J. Immunocytochemical staining of pS2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br J Surg. 1994 Aug;81(8):1155–1158. doi: 10.1002/bjs.1800810824. [DOI] [PubMed] [Google Scholar]
  40. Wright C., Nicholson S., Angus B., Sainsbury J. R., Farndon J., Cairns J., Harris A. L., Horne C. H. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992 Jan;65(1):118–121. doi: 10.1038/bjc.1992.22. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES